Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496807 · ClinicalTrials.gov registry record · Phase 1
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01496807 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 31 participants.
The verdict
NCT01496807, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to see how much of the drug Yervoy can be safely tolerated when it is given to people who are also receiving a drug called Sylatron. Investigators also wish to find out whether the addition of Yervoy increases the chance that Sylatron will cause a rise in the level of antibodies in the patient's blood that recognize their own tissues, known as "autoimmune" antibodies. Investigators also want to find out how likely it is that their tumor will shrink.
Interventions
- DRUG Yervoy
- DRUG Sylatron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2012-02-17 |
| Est. Completion | 2016-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496807
The ClinicalTrials.gov registry entry for NCT01496807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Yervoy is the first listed.
NCT01496807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496807 about?
NCT01496807 is a clinical study titled "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma". The purpose of this study is to see how much of the drug Yervoy can be safely tolerated when it is given to people who are also receiving a drug called Sylatron. Investigators also wish to find out whether the addition of Yervoy increases the chance that Sylatron will cause a rise in the level of an...
What is the current status of trial NCT01496807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2012-02-17. Estimated completion is 2016-08-29.
What interventions are being tested in trial NCT01496807?
The interventions under investigation include: Yervoy (DRUG), Sylatron (DRUG).
Who is sponsoring clinical trial NCT01496807?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.